Morphic Medical Inc. appoints new CFO

The Board of Crystal Amber Fund is pleased to see the announcement by Morphic Medical Inc. ("Morphic Medical"), the medical device company that has pioneered minimally invasive treatments of obesity and cardiometabolic disorders in which it owns 96.7% of the issued share capital, that it has appointed Jane Wright as its Chief Financial Officer.

Jane is a qualified accountant with over 30 years of experience including several senior financial and operational positions in international medical device companies, navigating complex regulatory environments and driving strategic growth and operational efficiency.

Prior to joining Morphic Medical, she served as Finance & Operations Director at Apollo Endosurgery, a specialist in endoluminal surgery (ELS) procedures which was acquired by Boston Scientific Corporation in 2022.

Jane's arrival follows the appointment of Mike Gutteridge as Chief Executive Officer in July and marks the latest milestone for the Morphic Medical business.

Following recent CE Mark certification and commercial registration by the UK's MHRA, RESET® is cleared for sale across key European markets, including Germany where rollout has already begun. In her new role, Wright will play a key role in shaping the company's long-term financial strategy and supporting its continued growth.

Research presented to the IFSO World Congress of obesity experts this month has shown that RESET® delivers substantial and durable benefits, with patients losing an average of 18.9% of their total body weight, while also improving blood sugar control.

Christopher Waldron, Chairman of Crystal Amber, commented: "We are pleased to see Morphic Medical strengthening its executive team as the momentum within the business continues to build."